MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.03.11.710889

Медицинская библиотека · bioRxiv : the preprint server for biology · 2026

Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy.

Zeidler Benjamin J, Thomas Connor, Salvas John P, Javier Areli Jannes S, Richards Alyssa M, Bean Linda A, Earl Conner C, Agrawal Akanksha, Narra Niharika, Zeng Lifan, Witczak Carol A, Huot Joshua R, Kim Il-Man, Madhur Meena S, Kowala Mark C, Markham Larry W, Goergen Craig J, Welc Steven S

СтатьяПрепринтПеревод в очереди

Аннотация

Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy without a cure. This study examined the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) on cardiac function in the dystrophin-deficient mdx mouse model of DMD. Male mice were fed control chow or EMPA-containing chow (~25 mg/kg/day), and cardiac function was evaluated longitudinally by four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or chamber volume but preserved ejection fraction (EF) for 12 weeks, maintained significantly higher EF through 24 weeks, and attenuated global impairment of systolic and diastolic myocardial deformation. These functional improvements were accompanied by reduced cardiomyocyte hypertrophy and decreased expression of cardiac stress genes. EMPA reduced mitochondrial DNA damage, increased mitochondrial DNA copy number, and induced transcriptional signatures consistent with enhanced fatty acid and ketone metabolism, contributing to increased myocardial ATP content. Systemically, EMPA improved body mass trajectory, preserved relative lean mass, enhanced skeletal muscle torque, and did not adversely affect renal function. Together, these findings demonstrate that EMPA improves cardiac performance and mitochondrial integrity while enhancing myocardial energy availability in mdx mice, supporting SGLT2 inhibitors as a promising therapeutic strategy for individuals with DMD.

Для цитирования: Zeidler Benjamin J, Thomas Connor, Salvas John P, Javier Areli Jannes S, Richards Alyssa M, Bean Linda A, Earl Conner C, Agrawal Akanksha, Narra Niharika, Zeng Lifan, Witczak Carol A, Huot Joshua R, Kim Il-Man, Madhur Meena S, Kowala Mark C, Markham Larry W, Goergen Craig J, Welc Steven S. Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy.. bioRxiv : the preprint server for biology. 2026. DOI: 10.64898/2026.03.11.710889.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.